Mednet Logo
HomeMedical OncologyQuestion

How would you modify neoadjuvant chemotherapy for a stage 2-3 triple negative breast cancer who has baseline grade 2-3 neuropathy?

1
3 Answers
Mednet Member
Mednet Member
Medical Oncology · Warren Alpert Medical School of Brown University

There are a few options I would consider. First, I would administer 4 cycles of dose-dense AC - assuming she has normal cardiac function at baseline - which typically has no significant neurotoxicity. If the patient has a very good response, I might stop there and send her to surgery. If she has had...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Medical Oncology · Washington University School of Medicine

The grade 2-3 chronic neuropathy poses a challenge for taxane chemotherapy. I would not use taxane in this setting. It would be helpful to know what is the etiology for the neuropathy and whether the comorbid condition also put her at a risk for anthracycline related cardiac toxicities. Oral CMF reg...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Medical Oncology · Onc Assocs of South Florida

Depends on the degree of the pre-existing neuropathy and if related to DM can be monitored or the dose altered in any case I would have a discussion with the patient and monitor closely if giving a taxane

Register or Sign In to see full answer